Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...
A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...
When I first started dating my husband, who has CF, it felt like diving straight into the deep end of the CF world. I was completely overwhelmed at first, but everything changed when I discovered a ...
Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...
I spent my childhood and young adulthood being told I was “too young and healthy” to be dealing with the health issues I experienced. But as an adult, I was determined to find answers, and eventually, ...
Irish Independent on MSN5d
Wicklow mother calls for access to life-saving therapy for son with rare form of Cystic FibrosisA Wicklow mother is among a concerned group of parents who are calling for individual trials of the modulator therapies for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback